Key facts
- This page summarizes Halley E. Gilbert's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jun 2024, 16:51.
Halley E. Gilbert - 14 Jun 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- Director
- Issuer ticker
- ARQT
- Reported as of
- 14 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jun 2024, 16:51:32 UTC
- Prior SEC filing
- 10 Jun 2024
- Next SEC filing
- 13 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Topper, as Attorney-in-Fact for Halley E. Gilbert
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Halley E. Gilbert filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 18 Jun 2024.
Change
- Previous filing in this sequence was filed on 10 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,139
- Change %
- +117%
- Price
- $0.000000
- Shares after
- 18,826
- Date
- 14 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARQT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +27,052
- Change %
- Price
- $0.000000
- Shares after
- 27,052
- Date
- 14 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,052
- Exercise price
- $8.63
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Footnote F2
The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.